AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
argenx SE
Video analysis: ARGX
All videosNo video analysis for this stock yet. Request one from our team.
News: ARGX
BenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug Discovery
TORONTO--(BUSINESS WIRE)--BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise agreement with argenx, a global immunology innovation company, to deploy EMET, BenchSci's agentic research environment for preclinical drug discovery, within the organization. Selected through a competitive evaluation led by argenx's own scientists, the agreement represents a significant milestone in BenchSci's expansion across European biopharma. U.
Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated?
Argenx's top and bottom lines are growing robustly. The company expects to report multiple pivotal clinical results through the second half of 2027.
argenx to Present at Upcoming Investor Conferences
September 1, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced that members of the management team will participate in the following investor conferences in September:
argenx Completes Acquisition of Forte Biosciences, Inc.
Acquisition adds first-in-class anti-CD122 Antibody, FB102, to argenx's immunology pipeline August 27, 2026 – 8:50 AM ET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company today announced the successful completion of the acquisition of Forte Biosciences, Inc. (“Forte”) (Nasdaq: FBRX). The acquisition expands argenx's portfolio of differentiated immunology medicines, adding FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease and potential to address multiple autoimmune diseases.
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Atlassian, Dick’s Sporting Goods, EPAM Systems, GoDaddy, Intuit, Jersey Mike’s Subs, JFrog, Lattice Semiconductor, and More
Wall Street analysts are reshuffling their bets ahead of a critical inflation report and NVIDIA earnings that could jolt markets in either direction. Find out which names got upgraded, cut, or newly covered before the opening bell Wednesday.
Argenx Just Landed Another Phase 3 Win -- and Wall Street May Be Missing the Bigger Story
Argenx recently announced Phase 3 results for Vyvgart Hytrulo in treating autoimmune myositis. While there was one disappointment with the clinical study, the results were positive overall.
argenx VYVGART Hits Phase III Goal in Autoimmune Myositis, Eyes IMNM Filing
argenx (NASDAQ: ARGX) reported positive top-line results from its Phase III ALKIVIA trial of VYVGART Hytrulo in autoimmune myositis, meeting its primary endpoint in a combined population of patients with immune-mediated necrotizing myopathy, or IMNM, and dermatomyositis, or DM. The study evaluated efgartigimod in a 52-week Phase II/III basket trial that enrolled patients with IMNM, DM
ARGX Announces Positive Phase III Data on Vyvgart Hytrulo, Stock Up
argenx's shares jump 16% as Vyvgart Hytrulo delivered positive phase III ALKIVIA data, supporting its potential label expansion in autoimmune myositis.
Similar companies
-
Becton, Dickinson and Company
BDX
·
New York Stock Exchange
Compare
-
Edwards Lifesciences Corporation
EW
·
New York Stock Exchange
Compare
-
Alnylam Pharmaceuticals, Inc.
ALNY
·
NASDAQ
Compare
-
Veeva Systems Inc.
VEEV
·
New York Stock Exchange
Compare
-
Regeneron Pharmaceuticals, Inc.
REGN
·
NASDAQ
Compare
-
Cardinal Health, Inc.
CAH
·
New York Stock Exchange
Compare